Mostafa et al., 2025 - Google Patents
A Live Attenuated Vaccine Candidate against Emerging Highly Pathogenic Cattle-Origin 2.3. 4.4 b H5N1 VirusesMostafa et al., 2025
View PDF- Document ID
- 12537030070769307318
- Author
- Mostafa A
- Ye C
- Barre R
- Shivanna V
- Meredith R
- Platt R
- Escobedo R
- Bayoumi M
- Castro E
- Jackson N
- Cupic A
- Nogales A
- Anderson T
- Sastre A
- Martinez-Sobrido L
- Publication year
- Publication venue
- bioRxiv
External Links
Snippet
Influenza viruses present a significant public health risk, causing substantial illness and death in humans each year. Seasonal flu vaccines must be updated regularly, and their effectiveness often decreases due to mismatches with circulating strains. Furthermore …
- 230000001717 pathogenic effect 0 title abstract description 22
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
- C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
- C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sanchez-Felipe et al. | A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate | |
| Steel et al. | Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza | |
| Baker et al. | Protection against lethal influenza with a viral mimic | |
| Tioni et al. | Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2 | |
| Kobinger et al. | Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques | |
| Romanova et al. | Preclinical evaluation of a replication-deficient intranasal ΔNS1 H5N1 influenza vaccine | |
| Qin et al. | Identification of novel T-cell epitopes on infectious bronchitis virus N protein and development of a multi-epitope vaccine | |
| Sheahan et al. | Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus | |
| Pena et al. | Restored PB1-F2 in the 2009 pandemic H1N1 influenza virus has minimal effects in swine | |
| Jang et al. | Association between interferon response and protective efficacy of NS1-truncated mutants as influenza vaccine candidates in chickens | |
| Liu et al. | Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters | |
| Gorres et al. | DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs | |
| Chen et al. | Efficacy of live-attenuated H9N2 influenza vaccine candidates containing NS1 truncations against H9N2 avian influenza viruses | |
| Penkert et al. | Saccharomyces cerevisiae-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease | |
| Holzer et al. | Immunogenicity and protective efficacy of seasonal human live attenuated cold-adapted influenza virus vaccine in pigs | |
| Ricklin et al. | Virus replicon particle vaccines expressing nucleoprotein of influenza A virus mediate enhanced inflammatory responses in pigs | |
| Mostafa et al. | A live attenuated NS1-deficient vaccine candidate for cattle-origin influenza A (H5N1) clade 2.3. 4.4. b viruses | |
| Leonard et al. | Development of DNA and mRNA-LNP vaccines against an H5N1 clade 2.3. 4.4 b influenza virus | |
| Beavis et al. | Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants | |
| Schön et al. | A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1 | |
| Jang et al. | Host defense mechanism-based rational design of live vaccine | |
| US20200129612A1 (en) | Genome-wide identification of immune evasion functions in a virus | |
| Nogales et al. | Mutation L319Q in the PB1 polymerase subunit improves attenuation of a candidate live-attenuated influenza A virus vaccine | |
| Mostafa et al. | A Live Attenuated Vaccine Candidate against Emerging Highly Pathogenic Cattle-Origin 2.3. 4.4 b H5N1 Viruses | |
| Chen et al. | Intranasal influenza-vectored COVID-19 vaccines confer broad protection against SARS-CoV-2 XBB variants in hamsters |